OpenNashEarnings

Daiichi Sankyo (4568) · Pharmaceuticals

Daiichi Sankyo Q2 FY2026 earnings: summary, key numbers & outlook

Results filed 30 Oct 2026 · Quarter ended 30 Sep 2026

Slides (40 pages)Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Daiichi Sankyo is scaling Enhertu and Datroway through new first-line approvals, a Summit Therapeutics combination deal and a single global commercialization unit launching April 2027.

Enhertu became the US market leader in first-line HER2-positive metastatic breast cancer and took the top share in adjuvant early breast cancer. Datroway has treated about 9,800 patients globally, roughly 1.4 times the prior quarter, and leads later-line EGFR-mutated lung cancer in the US. New approvals landed across the US, Europe, Japan and China. Non-oncology units such as American Regent and Lixiana were weaker.

Management is centralizing oncology and specialty commercialization into one unit from April 2027, aiming for 20+ indication launches by 2030 and a global top 5 oncology ranking by 2035. It also plans to test Datroway with Summit's ivonescimab. The tension is dependence on two drugs, with a withdrawn US filing for ifinatamab deruxtecan and a fast-moving small cell lung cancer field.

No call transcript for this quarter, so this summary also draws on: Investing.com ↗, Investing.com ↗.

Slides & documents

Open the slide deck (PDF, 40 pages) ↗

Daiichi Sankyo Q2 FY2026 slide deck, page 1Daiichi Sankyo Q2 FY2026 slide deck, page 2Daiichi Sankyo Q2 FY2026 slide deck, page 3Daiichi Sankyo Q2 FY2026 slide deck, page 4Daiichi Sankyo Q2 FY2026 slide deck, page 5Daiichi Sankyo Q2 FY2026 slide deck, page 6

Showing the first 6 of 40 pages.

Results documents

Key numbers

Revenue (six months)
JPY1,167.2 billion

up 19.7% year on year

Operating profit (six months) · GAAP
JPY193.8 billion

up 34.4% year on year

Profit attributable to owners of the Company · GAAP
JPY151.5 billion

up 15.8% year on year

Diluted earnings per share (six months) · GAAP
83.20

up from 70.52 a year ago

Core operating profit (six months) · non-GAAP
JPY221.3 billion

up 46.9% year on year

Net cash flows from operating activities (JPY millions) · GAAP
50.7B

from (28,311) a year ago

Segment or metricValueChange
Oncology Business UnitJPY422.6 billionup 54.8% year on year
Enhertu global product sales (six months)464.5 Bn JPYup 45.9% year on year
Datroway global product sales (six months)48.3 Bn JPYup 207.2% year on year
Datroway patients treated since launchapprox. 9,800approx. 1.4 times the prior quarter
Japan Business UnitJPY232.7 billiondown 6.9% year on year
American Regent UnitJPY77.9 billiondown 19.5% year on year
EU Specialty Business UnitJPY149.2 billionup 9.1% year on year
ASCA Business UnitJPY142.5 billionup 20.9% year on year
Where each number comes from
  • Revenue (six months): “Revenue in the first six months of the year ending March 31, 2027 increased by JPY191.9 billion, or 19.7% year on year, to JPY1,167.2 billion.”
  • Operating profit (six months): “Operating profit increased by JPY49.6 billion, or 34.4% year on year, to JPY193.8 billion.”
  • Profit attributable to owners of the Company: “Profit attributable to owners of the Company increased by JPY20.7 billion, or 15.8% year on year, to JPY151.5 billion.”
  • Diluted earnings per share (six months): “Basic earnings per share (JPY) 70.55 83.22 Diluted earnings per share (JPY) 70.52 83.20”
  • Core operating profit (six months): “Core operating profit increased by JPY70.6 billion, or 46.9% year on year, to JPY221.3 billion.”
  • Net cash flows from operating activities (JPY millions): “Net cash flows from (used in) operating (28,311) 50,738 activities Cash flows from investing activities Payments into time deposits (24,061) (5,563)”
  • Oncology Business Unit: “Revenue from the Unit increased by JPY149.6 billion, or 54.8% year on year, to JPY422.6 billion and the revenue in local currency increased by USD782 million”
  • Enhertu global product sales (six months): “Q2 Global Product Sales Result 464.5 Bn JPY 24.5 YoY +146.1 Bn JPY (+45.9%)”
  • Datroway global product sales (six months): “Q2 Global Product Sales Result 48.3 Bn JPY 7.0 YoY +32.6 Bn JPY (+207.2%)”
  • Datroway patients treated since launch: “Treated approx. 9,800 patients globally since launch, approx. 1.4 times the prior quarter”
  • Japan Business Unit: “Revenue from the Unit decreased by JPY17.2 billion, or 6.9% year on year, to JPY232.7 billion due to decreases in sales of Lixiana and others”
  • American Regent Unit: “Revenue from American Regent Unit decreased by JPY18.9 billion, or 19.5% year on year, to JPY77.9 billion”
  • EU Specialty Business Unit: “on a JPY basis, revenue was JPY149.2 billion, constituting an increase of JPY12.4 billion, or 9.1% year on year”
  • ASCA Business Unit: “Revenue from the Unit increased by JPY24.6 billion, or 20.9% year on year, to JPY142.5 billion due to the growth in sales of Enhertu in Brazil”

Copied from the press release ↗ and other documents in the company's results page ↗. A figure is published only if its sentence is in those documents.

Outlook

MetricPeriodOutlook
Revenue (JPY millions), unchanged from Julyfiscal year ending March 31, 20272,340,000
Basic earnings per share (JPY)fiscal year ending March 31, 2027137.94
Capital expenditure (JPY billions)fiscal 2026200.0
Annual dividend per share (JPY)fiscal 2026JPY100

Key takeaways

  1. Enhertu leads US first-line HER2+ metastatic breast cancer

    Enhertu is now the US market leader in HER2+ first-line metastatic breast cancer and holds the No.1 share in HER2+ adjuvant early breast cancer. First-line approvals in China, Japan and Europe in Aug–Sep 2026 widen the addressable base.

  2. Datroway patient base grew 1.4x in a quarter

    About 9,800 patients have been treated globally since launch, and new patient starts grew in all promoted indications. It leads later-line EGFR-mutated NSCLC in the US and is gaining early share in first-line TNBC.

  3. Summit deal pairs Datroway with ivonescimab

    Daiichi Sankyo and AstraZeneca will study Datroway with Summit's investigational PD-1/VEGF bispecific ivonescimab across multiple solid tumors, starting with first-line TNBC. Costs are shared and each party keeps rights to its own medicine.

  4. One global commercialization unit starts April 2027

    Oncology and specialty commercialization will be centralized into 5 regional businesses and 6 global functions. Management cites 20+ anticipated indication launches by 2030 as the reason.

  5. Ifinatamab deruxtecan US filing withdrawn; Enhertu lung data positive

    The US application for I-DXd in previously treated small cell lung cancer was voluntarily withdrawn in September 2026. Separately, DESTINY-Lung04 showed Enhertu beating pembrolizumab plus chemotherapy as first-line treatment for HER2-mutant NSCLC.

Questions

What were Daiichi Sankyo's main product developments this quarter?

Enhertu and Datroway gained first-line approvals across the US, Europe, Japan and China, and Enhertu became US market leader in first-line HER2+ metastatic breast cancer. Datroway treated about 9,800 patients, 1.4 times the prior quarter.

What is the Summit Therapeutics collaboration?

Daiichi Sankyo and AstraZeneca will combine Datroway with Summit's investigational PD-1/VEGF antibody ivonescimab, with trial costs shared and each company keeping rights to its own medicine. The first Phase 3 study is in first-line triple-negative breast cancer.

How is Daiichi Sankyo changing its go-to-market organization?

From April 2027 it will run oncology and specialty commercialization as one global unit, with 5 regional businesses and 6 global functions. The goal is better resource allocation and standardized processes.

What happened with ifinatamab deruxtecan (I-DXd)?

Daiichi Sankyo voluntarily withdrew its US application for previously treated extensive-stage small cell lung cancer in September 2026, after the filing was accepted with priority review in April. The Phase 3 IDeate-Lung02 readout is expected in FY2027.

What upcoming pipeline readouts matter for Datroway?

TROPION-Lung15 is expected in FY2026 H2, and AVANZAR in CY2027 H1. TROPION-Lung07, Lung08, Breast03 and Breast05 are also due in FY2027.

Call recording

Listen to the official replay ↗